Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 2.2 billion by 2030. The market is driven by factors such as increasing incidence of cancer, rising awareness about the adverse effects of chemotherapy, and technological advancements in drug development.
HT3 Inhibitors segment accounted for the largest share in 2018 due to their efficacy in treating nausea and vomiting caused by highly emetogenic chemotherapy drugs. NK1 Inhibitors segment is expected to grow at a CAGR of 6% during the forecast period due to their efficacy in treating nausea and vomiting caused by moderately emetogenic chemotherapy drugs. High-emetic chemotherapeutic agents are used for treatment of cancers that have high risk for recurrence or metastasis such as breast cancer, lung cancer, colon cancer etc, whereas low-emetic chemotherapeutic agents are used for treatment of cancers with low risk for recurrence or metastasis such as prostate cancer etc, which leads to higher demand from patients suffering from high-emetic chemotherapeutic agents than those suffering from low-emetic chemotherapeutic agents.
-The global CINV drugs market is expected to grow at a CAGR of 4.5% from 2017 to 2022.
-The US is the largest market for CINV drugs, accounting for over 50% of the total revenue in 2016.
Industry Growth Insights published a new data on “ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market”. The research report is titled “ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market research by Types (5-HT3 Inhibitors, NK1 Inhibitors, Other), By Applications (Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, Other), By Players/Companies GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro”.
Scope Of The Report
Report Attributes
Report Details
Report Title
ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Research Report
By Type
5-HT3 Inhibitors, NK1 Inhibitors, Other
By Application
Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, Other
By Companies
GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
 Drugs Industry Outlook.svg)
Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Report Segments:
The global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market is segmented on the basis of:
Types
5-HT3 Inhibitors, NK1 Inhibitors, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Helsinn
- Heron Therapeutics
- Merck
- Tesaro
 Drugs Market Overview.svg)
Highlights of The ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5-HT3 Inhibitors
- NK1 Inhibitors
- Other
- By Application:
- Highly Emetogenic Chemotherapy
- Moderately Emetogenic Chemotherapy
- Low Emetogenic Chemotherapy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chemotherapy induced nausea and vomiting (CINV) drugs are medications that can help to prevent or reduce the symptoms of CINV. These drugs can work by blocking certain chemicals that may cause nausea and vomiting.
Some of the major companies in the chemotherapy induced nausea and vomiting (cinv) drugs market are GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro.
The chemotherapy induced nausea and vomiting (cinv) drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market - Supply Chain
4.5. Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Forecast
4.5.1. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Absolute $ Opportunity
5. Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Type
5.3.1. 5-HT3 Inhibitors
5.3.2. NK1 Inhibitors
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Application
6.3.1. Highly Emetogenic Chemotherapy
6.3.2. Moderately Emetogenic Chemotherapy
6.3.3. Low Emetogenic Chemotherapy
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Demand Share Forecast, 2019-2026
9. North America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Application
9.4.1. Highly Emetogenic Chemotherapy
9.4.2. Moderately Emetogenic Chemotherapy
9.4.3. Low Emetogenic Chemotherapy
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Type
9.7.1. 5-HT3 Inhibitors
9.7.2. NK1 Inhibitors
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Demand Share Forecast, 2019-2026
10. Latin America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Application
10.4.1. Highly Emetogenic Chemotherapy
10.4.2. Moderately Emetogenic Chemotherapy
10.4.3. Low Emetogenic Chemotherapy
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Type
10.7.1. 5-HT3 Inhibitors
10.7.2. NK1 Inhibitors
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Demand Share Forecast, 2019-2026
11. Europe ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Application
11.4.1. Highly Emetogenic Chemotherapy
11.4.2. Moderately Emetogenic Chemotherapy
11.4.3. Low Emetogenic Chemotherapy
11.4.4. Other
11.5. Basis Point Shar (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Type
11.7.1. 5-HT3 Inhibitors
11.7.2. NK1 Inhibitors
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Demand Share, 2019-2026
12. Asia Pacific ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Application
12.4.1. Highly Emetogenic Chemotherapy
12.4.2. Moderately Emetogenic Chemotherapy
12.4.3. Low Emetogenic Chemotherapy
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Type
12.7.1. 5-HT3 Inhibitors
12.7.2. NK1 Inhibitors
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Demand Share, 2019-2026
13. Middle East & Africa ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Application
13.4.1. Highly Emetogenic Chemotherapy
13.4.2. Moderately Emetogenic Chemotherapy
13.4.3. Low Emetogenic Chemotherapy
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Size and Volume Forecast by Type
13.7.1. 5-HT3 Inhibitors
13.7.2. NK1 Inhibitors
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market: Market Share Analysis
14.2. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Distributors and Customers
14.3. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Helsinn
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Heron Therapeutics
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Tesaro
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
